A new bipartisan Senate proposal could reshape access to one of the most effective medications for opioid use disorder by allowing certain physicians to prescribe methadone for pickup at community pharmacies. The Modernizing Opioid Treatment Access Act 2.0, introduced by Sens. Ed Markey and Rand Paul, would move methadone treatment beyond the highly restricted opioid treatment program model that currently governs most access in the United States.

A new class of synthetic opioids known as nitazenes is drawing urgent attention from public health and addiction experts as the U.S. drug supply becomes increasingly unpredictable and lethal. Recent reporting from STAT and Bellingcat says nitazenes are spreading rapidly across the country and, in some forms, may be up to 40 times more potent than fentanyl. The investigation found that 48 of 50 states have reported nitazene seizures, underscoring how quickly these substances are moving into the illicit market.

The U.S. Food and Drug Administration has approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter use, expanding access to a critical medication used to reverse opioid overdose. According to the FDA, consumers will be able to purchase Rextovy without a prescription at pharmacies, convenience stores, and online, marking another step forward in broadening access to naloxone as the nation continues to confront the opioid crisis.

The Cherokee Nation is using opioid settlement funds to build a new treatment center in Tahlequah, Oklahoma, offering a powerful example of how communities are translating settlement dollars into long-term addiction treatment and recovery infrastructure. According to recent reporting, the new 45,000-square-foot facility will include 100 inpatient beds, outpatient services, and follow-up support designed to meet the needs of tribal citizens affected by the ongoing opioid crisis.

A growing shift in the treatment of alcohol use disorder (AUD) is reshaping how clinicians, health systems, and recovery communities think about care. Recent reporting from STAT highlights a move away from a one-size-fits-all model centered solely on abstinence and toward a broader treatment landscape that includes medication for alcohol use disorder, moderation-focused approaches for some patients, and alternatives to traditional peer support models such as Alcoholics Anonymous.

A New York Times report is drawing new attention to the intersection of vaping regulation, FDA oversight, and political influence in public health policy. According to the report, Reynolds American donated $5 million to MAGA Inc., a super PAC supporting President Donald Trump, about a week before the administration announced a new e-cigarette policy that could benefit major tobacco companies seeking to expand sales of flavored vaping products. The donation was made on April 30 through a Reynolds subsidiary and brought that subsidiary’s total giving to the PAC to $8 million.

New federal data show that U.S. drug overdose deaths declined for the third straight year in 2025, a notable milestone in the nation’s response to the opioid epidemic and broader overdose crisis. According to provisional CDC figures, about 70,000 Americans died of overdoses in 2025, down roughly 14% from 2024 and back to levels last seen before the COVID-19 pandemic. The decline marks the longest sustained drop in overdose deaths in decades and reflects progress across much of the country.

New research in the Journal of Substance Use & Addiction Treatment highlights the growing potential of smart harm reduction vending machines as a low-barrier strategy for improving overdose prevention, public health access, and community-based support services. The study evaluated two “smart” vending machines placed in community settings and found that this model can help expand access to naloxone, health supplies, and other harm reduction resources while also connecting users to local services through touchscreen technology and anonymous data collection.

A new federal policy shift is intensifying debate around harm reduction, overdose prevention, and the nation’s response to the fentanyl crisis. The Trump administration, through updated guidance from the Substance Abuse and Mental Health Services Administration, has ended the use of certain federal grant funds for fentanyl test strips and other substance test kits distributed for individual use, reversing prior federal support for these tools.

Purdue Pharma, the maker of OxyContin, has officially ceased operations as part of its long-running bankruptcy resolution, marking a major milestone in the ongoing response to the opioid epidemic. The company is being replaced by Knoa Pharma, a new public benefit corporation that will operate under independent oversight and direct its net profits toward efforts to address opioid addiction, prevention, treatment, and recovery.

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to the growing role of psychedelic research in mental health treatment, addiction care, and veteran health. The order is intended to accelerate research into psychedelic therapies and support faster review of certain investigational treatments already moving through the FDA process.

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy. The U.S. Department of Justice has moved state-licensed medical marijuana from Schedule I to Schedule III, signaling a historic shift in how medical cannabis is regulated at the federal level. While the order does not legalize marijuana under federal law, it does reduce regulatory barriers, expand opportunities for cannabis research, and allow licensed medical marijuana businesses to deduct standard business expenses on federal taxes.